Genentech licenses Alector brain-penetrant Parkinson's programme in deal worth up to $1.27bn
Genentech has licensed Alector's brain-penetrant AL050 programme in a neurodegeneration deal worth up to $1.27 billion.
Alector will receive $100 million upfront and could earn up to $1.17 billion in development, regulatory and commercial milestones, plus tiered royalties.
AL050 is a preclinical GCase enzyme replacement therapy using Alector's Brain Carrier platform to cross the blood-brain barrier and is being developed for Parkinson's disease.
Field | Content |
Article Type | Deals |
Companies | Genentech; Alector |
Deal Type | Exclusive global licensing agreement |
Key Asset | AL050 |
Therapy Area | Parkinson's disease; neurodegeneration |
Technology/Modality | Brain-penetrant GCase enzyme replacement therapy |
Platform | Alector Brain Carrier |
Development Stage | Preclinical |
Upfront Payment | $100 million |
Potential Milestones | Up to $1.17 billion |
Potential Deal Value | Up to $1.27 billion |
Additional Economics | Tiered royalties |
Geography | Worldwide |
What Happened | Genentech secured exclusive worldwide rights to Alector's AL050 programme. |
Why It Matters | The transaction gives Genentech access to a blood-brain-barrier delivery platform designed to enable enzyme replacement therapy in neurodegenerative disease. |
Supporting Context | AL050 is designed to deliver GCase into the brain using Alector's Brain Carrier technology. |
Strategic Rationale | Genentech is expanding its neurodegeneration pipeline with a differentiated approach to brain delivery, while Alector monetises a preclinical programme and platform capability. |
Potential Impact | If successful, AL050 could support a new disease-modifying treatment approach in Parkinson's disease. |
Key Takeaway | Genentech has licensed AL050 from Alector in a deal worth up to $1.27 billion. |
What to Watch | IND-enabling work, entry into clinical development and early evidence of brain penetration and GCase activity. |
Primary Source | Alector |
Relevant Date | 5 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments